Akèy › Limfom selil mantèl › Washington › Seattle
Etid klinik pou Limfom selil mantèl nan Seattle, WA
12 etid pou Limfom selil mantèl ap chèche patisipan nan sit nan ak bò kote Seattle (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Ap rekriteFaz 1/2
- Research Site, Seattle
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
- Fred Hutchinson Cancer Research Center, Seattle
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Ap rekriteFaz 1/2
- Fred Hutchinson Cancer Research Center, Seattle
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
- Swedish Cancer Institute (SCI), Seattle
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- Fred Hutchinson Cancer Center, Seattle
DALY II USA/ MB-CART2019.1 for DLBCL
Ap rekriteFaz 2
- Fred Hutchinson Cancer Center, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Ap rekriteFaz 2Volontè an sante akeyi
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
Ap rekriteFaz 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Study of SGR-1505 in Mature B-Cell Neoplasms
Ap rekriteFaz 1
- Fred Hutchinson Cancer Center, Seattle
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
Ap rekriteFaz 1
- Providence Swedish Cancer Institute, Seattle
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Seattle
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Ap rekriteFaz 1
- Swedish Cancer Institute, Seattle
Etid Limfom selil mantèl nan lòt vil
- Baldwin Park, CA15 etid
- Houston, TX15 etid
- Durham, NC13 etid
- New York City, NY12 etid
- Milwaukee, WI12 etid
- Boston, MA11 etid
- Columbus, OH11 etid
- Nashville, TN11 etid
- Chicago, IL10 etid
- Portland, OR9 etid
- Rochester, MN9 etid
- St. Louis, MO8 etid
Lòt etid nan Seattle
- Kansè Poumon ki pa ti selil53 etid
- Kansè (tout kalite)49 etid
- Kansè pwostat42 etid
- Leksemi mieloïd egi40 etid
- Kansè nan tete39 etid
- Kansè Metastatik39 etid
- Kansè kolorektal34 etid
- Kansè poumon33 etid
- Kansè ovè30 etid
- Myelom Miltip22 etid
- Sendwòm myelodisplastik21 etid
- Leksemi limfoblastik egi21 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.